Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer?

Christopher T. Chen, Richard K Valicenti, Jiandong Lu, Troy Derose, Adam P. Dicker, Stephen E. Strup, S. Grant Mulholland, Irvin H. Hirsch, David E. McGinnis, Leonard G. Gomella

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: We evaluated the effect of three-dimensional conformal radiation therapy (3D-CRT) with or without hormonal therapy (HT) on sexual function (SF) in prostate cancer patients whose SF was known before all treatment. Methods and Materials: Between March 1996 and March 1999, 144 patients received 3D-CRT (median dose = 70.2 Gy, range 66.6-79.2 Gy) for prostate cancer and had pre- and post-therapy SF data. All SF data were obtained with the O'Leary Brief SF Inventory, a self-administered, multidimensional, validated instrument. We defined total sexual potency as erections firm enough for penetration during intercourse. Mean follow-up time was 21 months (SD ± 11 months). The Wilcoxon signed-rank test was used to test for significance of the change from baseline. Results: Before 3D-CRT, 87 (60%) of 144 men were totally potent as compared to only 47 (47%) of 101 at 1-year follow-up. Of the 60 men totally potent at baseline and followed for at least 1 year, 35 (58%) remained totally potent. These changes corresponded to a significant reduction in SF (p < 0.05). Patients who had 3D-CRT alone were more likely to be totally potent at 1 year than those receiving 3D-CRT with HT (56% vs. 31%, p = 0.012); however, they were also more likely to be potent at baseline (71% vs. 44%, p = 0.001). Although these two groups had a significant reduction in SF from baseline, their change was not significantly different from each other. Conclusion: These data indicate that 3D-CRT causes a significant reduction in total sexual potency as compared to pretreatment baseline. The addition of HT does not appear to increase the risk of sexual dysfunction.

Original languageEnglish (US)
Pages (from-to)591-595
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume50
Issue number3
DOIs
StatePublished - Jul 1 2001
Externally publishedYes

Fingerprint

radiation therapy
therapy
Prostatic Neoplasms
Radiotherapy
cancer
Therapeutics
rank tests
Nonparametric Statistics
pretreatment
penetration
Equipment and Supplies
dosage
causes

Keywords

  • Conformal radiation therapy
  • Hormonal therapy
  • Potency
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer? / Chen, Christopher T.; Valicenti, Richard K; Lu, Jiandong; Derose, Troy; Dicker, Adam P.; Strup, Stephen E.; Mulholland, S. Grant; Hirsch, Irvin H.; McGinnis, David E.; Gomella, Leonard G.

In: International Journal of Radiation Oncology Biology Physics, Vol. 50, No. 3, 01.07.2001, p. 591-595.

Research output: Contribution to journalArticle

Chen, Christopher T. ; Valicenti, Richard K ; Lu, Jiandong ; Derose, Troy ; Dicker, Adam P. ; Strup, Stephen E. ; Mulholland, S. Grant ; Hirsch, Irvin H. ; McGinnis, David E. ; Gomella, Leonard G. / Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer?. In: International Journal of Radiation Oncology Biology Physics. 2001 ; Vol. 50, No. 3. pp. 591-595.
@article{9fc6fe8ae7d145e8897e81a05174c085,
title = "Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer?",
abstract = "Purpose: We evaluated the effect of three-dimensional conformal radiation therapy (3D-CRT) with or without hormonal therapy (HT) on sexual function (SF) in prostate cancer patients whose SF was known before all treatment. Methods and Materials: Between March 1996 and March 1999, 144 patients received 3D-CRT (median dose = 70.2 Gy, range 66.6-79.2 Gy) for prostate cancer and had pre- and post-therapy SF data. All SF data were obtained with the O'Leary Brief SF Inventory, a self-administered, multidimensional, validated instrument. We defined total sexual potency as erections firm enough for penetration during intercourse. Mean follow-up time was 21 months (SD ± 11 months). The Wilcoxon signed-rank test was used to test for significance of the change from baseline. Results: Before 3D-CRT, 87 (60{\%}) of 144 men were totally potent as compared to only 47 (47{\%}) of 101 at 1-year follow-up. Of the 60 men totally potent at baseline and followed for at least 1 year, 35 (58{\%}) remained totally potent. These changes corresponded to a significant reduction in SF (p < 0.05). Patients who had 3D-CRT alone were more likely to be totally potent at 1 year than those receiving 3D-CRT with HT (56{\%} vs. 31{\%}, p = 0.012); however, they were also more likely to be potent at baseline (71{\%} vs. 44{\%}, p = 0.001). Although these two groups had a significant reduction in SF from baseline, their change was not significantly different from each other. Conclusion: These data indicate that 3D-CRT causes a significant reduction in total sexual potency as compared to pretreatment baseline. The addition of HT does not appear to increase the risk of sexual dysfunction.",
keywords = "Conformal radiation therapy, Hormonal therapy, Potency, Prostate cancer",
author = "Chen, {Christopher T.} and Valicenti, {Richard K} and Jiandong Lu and Troy Derose and Dicker, {Adam P.} and Strup, {Stephen E.} and Mulholland, {S. Grant} and Hirsch, {Irvin H.} and McGinnis, {David E.} and Gomella, {Leonard G.}",
year = "2001",
month = "7",
day = "1",
doi = "10.1016/S0360-3016(01)01504-8",
language = "English (US)",
volume = "50",
pages = "591--595",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer?

AU - Chen, Christopher T.

AU - Valicenti, Richard K

AU - Lu, Jiandong

AU - Derose, Troy

AU - Dicker, Adam P.

AU - Strup, Stephen E.

AU - Mulholland, S. Grant

AU - Hirsch, Irvin H.

AU - McGinnis, David E.

AU - Gomella, Leonard G.

PY - 2001/7/1

Y1 - 2001/7/1

N2 - Purpose: We evaluated the effect of three-dimensional conformal radiation therapy (3D-CRT) with or without hormonal therapy (HT) on sexual function (SF) in prostate cancer patients whose SF was known before all treatment. Methods and Materials: Between March 1996 and March 1999, 144 patients received 3D-CRT (median dose = 70.2 Gy, range 66.6-79.2 Gy) for prostate cancer and had pre- and post-therapy SF data. All SF data were obtained with the O'Leary Brief SF Inventory, a self-administered, multidimensional, validated instrument. We defined total sexual potency as erections firm enough for penetration during intercourse. Mean follow-up time was 21 months (SD ± 11 months). The Wilcoxon signed-rank test was used to test for significance of the change from baseline. Results: Before 3D-CRT, 87 (60%) of 144 men were totally potent as compared to only 47 (47%) of 101 at 1-year follow-up. Of the 60 men totally potent at baseline and followed for at least 1 year, 35 (58%) remained totally potent. These changes corresponded to a significant reduction in SF (p < 0.05). Patients who had 3D-CRT alone were more likely to be totally potent at 1 year than those receiving 3D-CRT with HT (56% vs. 31%, p = 0.012); however, they were also more likely to be potent at baseline (71% vs. 44%, p = 0.001). Although these two groups had a significant reduction in SF from baseline, their change was not significantly different from each other. Conclusion: These data indicate that 3D-CRT causes a significant reduction in total sexual potency as compared to pretreatment baseline. The addition of HT does not appear to increase the risk of sexual dysfunction.

AB - Purpose: We evaluated the effect of three-dimensional conformal radiation therapy (3D-CRT) with or without hormonal therapy (HT) on sexual function (SF) in prostate cancer patients whose SF was known before all treatment. Methods and Materials: Between March 1996 and March 1999, 144 patients received 3D-CRT (median dose = 70.2 Gy, range 66.6-79.2 Gy) for prostate cancer and had pre- and post-therapy SF data. All SF data were obtained with the O'Leary Brief SF Inventory, a self-administered, multidimensional, validated instrument. We defined total sexual potency as erections firm enough for penetration during intercourse. Mean follow-up time was 21 months (SD ± 11 months). The Wilcoxon signed-rank test was used to test for significance of the change from baseline. Results: Before 3D-CRT, 87 (60%) of 144 men were totally potent as compared to only 47 (47%) of 101 at 1-year follow-up. Of the 60 men totally potent at baseline and followed for at least 1 year, 35 (58%) remained totally potent. These changes corresponded to a significant reduction in SF (p < 0.05). Patients who had 3D-CRT alone were more likely to be totally potent at 1 year than those receiving 3D-CRT with HT (56% vs. 31%, p = 0.012); however, they were also more likely to be potent at baseline (71% vs. 44%, p = 0.001). Although these two groups had a significant reduction in SF from baseline, their change was not significantly different from each other. Conclusion: These data indicate that 3D-CRT causes a significant reduction in total sexual potency as compared to pretreatment baseline. The addition of HT does not appear to increase the risk of sexual dysfunction.

KW - Conformal radiation therapy

KW - Hormonal therapy

KW - Potency

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0035400368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035400368&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(01)01504-8

DO - 10.1016/S0360-3016(01)01504-8

M3 - Article

VL - 50

SP - 591

EP - 595

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -